FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hykes Andrew</u>				Issuer Name and Ticker or Trading Symbol     Inari Medical, Inc. [ NARI ]								ck all ap Dire	nip of Reportion oplicable) ector cer (give title	Othe	Owner r (specify			
(Last) (First) (Middle) C/O INARI MEDICAL, INC. 9 PARKER, SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 02/11/2021								^	beid	below) below)  Chief Operating Officer					
(Street) IRVINE	NE CA 92618			4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(St		Zip)	tivo	tive Securities Acquired, Disposed of, or Benef								ficially Owned					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date,		l Pate,	3. Transaction Code (Instr. 4. Securities Ac Disposed Of (D)			Acqui				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) o	r Pric	e	Repo	orted saction(s) r. 3 and 4)	(	(		
Common	Stock		02/11/2021	$\top$			Α		16,030(1)	A	$\top$	\$0.00		211,971	D			
Common	Stock		02/19/2021				S <sup>(2)</sup>		300	D	4	3115.04	2	211,671	D			
Common	Stock		02/19/2021				<b>S</b> <sup>(2)</sup>		1,501	D	\$13	16.4813 <sup>©</sup>	3)	210,170	D			
Common	Stock		02/19/2021				S <sup>(2)</sup>		4,672	D	\$1	L7.6703 <sup>(</sup>	) [	205,498	D			
Common	Stock		02/19/2021				<b>S</b> <sup>(2)</sup>		1,507	D	\$13	l8.6171 <sup>(§</sup>	9	203,991	D			
Common	Stock		02/19/2021				<b>S</b> <sup>(2)</sup>		1,020	D	\$13	19.3796 <sup>(6</sup>	9) [	202,971	D			
Common	Stock													1,550	I	By Child 1		
Common	Common Stock												1,550		I	By Child 2		
Common Stock												1,550		I	By Child 3			
Common Stock												1,000		I	By Spouse			
		Та	ble II - Derivati (e.g., pu						oisposed ons, convei				Owne	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Yea		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans	4. Transaction of Code (Instr. 8) Se Ac (A) Di:		vative irities ired rosed ) r. 3, 4		Exercisable and ion Date Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of erivative ecurity estr. 5)		Ownersh Form: y Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
F	n of Respons			Code	v	(A) (		ate xercisa	Expirat able Date		or No of	ımber	per					

- 1. 2021 Annual RSU grant vesting Commencement date Jan-1-2021, 1/16th of the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date.
- 2. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
- 3. This transaction was executed in multiple trades at prices ranging from \$116.13 to \$116.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. This transaction was executed in multiple trades at prices ranging from \$117.25 to \$118.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 5. This transaction was executed in multiple trades at prices ranging from \$118.25 to \$119.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 6. This transaction was executed in multiple trades at prices ranging from \$119.31 to \$119.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

## Remarks:

/s/ Angela Ahmad, attorneyin-fact for Andrew Hykes

02/23/2021

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.